Menu
Back to User profile » Dr Peter Tóth
Papers published by Dr Peter Tóth:
Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients
Toth PP, Philip S, Hull M, Granowitz C
Vascular Health and Risk Management 2019, 15:533-538
Published Date: 4 December 2019
Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease
Power TP, Ke X, Zhao Z, Bonine NG, Cziraky MJ, Grabner M, Barron JJ, Quimbo R, Vangerow B, Toth PP
Vascular Health and Risk Management 2018, 14:23-36
Published Date: 5 February 2018
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
Blom DJ, Dent R, Castro RC, Toth PP
Vascular Health and Risk Management 2016, 12:185-197
Published Date: 9 May 2016
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Toth PP
Vascular Health and Risk Management 2016, 12:171-183
Published Date: 6 May 2016
Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease
Toth PP
Vascular Health and Risk Management 2015, 11:9-23
Published Date: 23 December 2014
Dyslipidemia in women: etiology and management
Phan BAP, Toth PP
International Journal of Women's Health 2014, 6:185-194
Published Date: 7 February 2014
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K
Vascular Health and Risk Management 2013, 9:719-727
Published Date: 15 November 2013
Ezetimibe therapy: mechanism of action and clinical update
Phan BAP, Dayspring TD, Toth PP
Vascular Health and Risk Management 2012, 8:415-427
Published Date: 3 July 2012